Welcome to Plenary Session.

I'm Vinay Prasad. I'm an associate professor with University of California, San Francisco.

I'm a practicing he-mong doctor, and my interests are medicine, oncology, and health policy.

And that's what you're going to get on Plenary Session.

This is season four, hashtag zero COVID.

It's zero COVID because we're not going to talk about COVID.

We're back, oncology, medicine, health policy.

We've got a lot in store for you.

But first, a plug.

If you like this podcast, leave us a rating or write us a review. It helps new listeners find the show. You can follow us on Twitter at Plenary underscore Session. You can email us at plenary session podcast at gmail.com. Give us your suggestions on what we should be covering. And we got a new YouTube channel, Vinay Prasad, MDMPH. Follow us on YouTube. I'm putting up a 10-part series on reading and interpreting cancer clinical trials.

You'll want to watch it there.

And if you really love this show, you can back us on patreon.com.

Patreon backers get access to slides for lectures I give on Plenary Session.

And with that, let's start the show.

I'm back in plenary session. On the Road edition, I'm joined by Dr. Jeffrey Bien.

Dr. Bien is a fellow at hematology oncology at Stanford University, and he was the chief resident at OHSU, where our paths cross for better or worse. We're talking about the new paper,

first-line nivolomab plus chemotherapy versus chemotherapy alone for advanced gastric, gastric, gastricisophageal junction, or esophageal

adenocarsinoma, checkmate, 649. Jeff, it's great to see you again.

Thanks for having me. A long-time listener, first-time caller.

First-time caller. Well, maybe last time caller. Depends on how it goes. Okay, so you've presented this paper before at your resident journal club.

Is that fair to say?

Yeah, in our fellowship journal club a couple months ago before the manuscript came out

...